玛伐凯泰Mavacamten 2.5mg

This product is indicated for the treatment of adult patients with obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) Functional Class II–III, to improve exercise capacity and symptoms.

The recommended initial dose is 5 mg orally once daily, administered without regard to food. Subsequent dose adjustments may be made to 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily. Swallow the capsules whole. Do not crush, open, or chew the capsules. Concomitant Use with Weak CYP2C19 Inhibitors or Moderate CYP3A4 Inhibitors For patients who are stably receiving treatment with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor, initiate treatment with this product at the recommended initial dose (5 mg orally once daily). For patients already receiving treatment with this product who are planned to initiate a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor, reduce the dose of this product by one level (i.e., 15 mg → 10 mg; 10 mg → 5 mg; 5 mg → 2.5 mg).

Concomitant use with moderate to potent CYP2C19 inhibitors or potent CYP3A4 inhibitors is prohibited. Concomitant use with moderate to potent CYP2C19 inducers or moderate to potent CYP3A4 inducers is prohibited.

Initiation of treatment with this product is not recommended for patients with left ventricular ejection fraction (LVEF) < 55%. Inform females of reproductive potential about the potential risk to the fetus if maternal exposure to this product occurs during pregnancy.

Syncope, dizziness.

60 capsules per bottle.

Store in a sealed container below 30℃. Keep out of the reach of children.